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ABSTRACT
Adenoid cystic carcinoma (ACC), the second most common salivary gland 
malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to 
progress to clinically advanced metastatic disease. Due to high long-term mortality 
and lack of effective systemic treatment, the slow-growing but aggressive ACC poses 
a particular challenge in head and neck oncology. Despite the advancements in cancer 
genomics, up until recently relatively few genetic alterations critical to the ACC 
development have been recognized. Although the specific chromosomal translocations 
resulting in MYB-NFIB fusions provide insight into the ACC pathogenesis and represent 
attractive diagnostic and therapeutic targets, their clinical significance is unclear, and 
a substantial subset of ACCs do not harbor the MYB-NFIB translocation. Strategies 
based on detection of newly described genetic events (such as MYB activating 
super-enhancer translocations and alterations affecting another member of MYB 
transcription factor family-MYBL1) offer new hope for improved risk assessment, 
therapeutic intervention and tumor surveillance. However, the impact of these 
approaches is still limited by an incomplete understanding of the ACC biology, and 
the manner by which these alterations initiate and drive ACC remains to be delineated. 
This manuscript summarizes the current status of gene fusions and other driver 
genetic alterations in ACC pathogenesis and discusses new therapeutic strategies 
stemming from the current research.
INTRODUCTION
Recurrent chromosomal translocations and resultant 
gene fusions have long been recognized as critical events 
in the oncogenesis of hematological malignancies and 
soft-tissue neoplasms. The important role of recurrent 
gene fusions in epithelial malignancies started to emerge 
recently with the advent of new genome-wide profiling 
technologies. It is now recognized that actionable gene 
fusions are prevalent among carcinomas with over 9,100 
documented translocations in solid tumors and over 176 of 
these described as recurrent events [1]. Although PLAG1 
rearrangements characterizing pleomorphic adenoma 
have been known for almost two decades [2], the role 
of recurrent chromosomal aberrations in other types of 
salivary gland tumors had not been understood until now. 
Recent advances such as the identification of 
MECT1-MAML2 fusion in mucoepidermoid carcinoma 
(MEC), the recognition of a new disease entity (mammary 
analogue secretory carcinoma [MASC]) characterized 
by the ETV6-NTRK3 fusion gene and the discovery of 
the MYB-NFIB oncogene in adenoid cystic carcinoma 
(ACC), have begun to refine our knowledge of salivary 
gland carcinogenesis [3]. ACC, one of the most common 
salivary gland malignancies, represents a significant 
challenge in head and neck oncology due to its aggressive 
and unpredictable phenotype. Given the high rate of late 
local recurrence and distant metastasis, ACC patients 
require intensive oncological surveillance. Unfortunately, 
with no effective systemic therapy available, the long-
term disease control is poor and overall disease-associated 
mortality remains high. The discovery of the translocation 
between chromosome 6q and 9p and the identification 
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of the resultant MYB-NFIB fusion in 2009, led to an 
important insight into the molecular pathogenesis of this 
malignancy and highlighted the tumor driving role of 
the MYB (myeloblastosis) proto-oncogene [4]. Recently, 
the identification of chromosomal rearrangements that 
juxtapose super-enhancers to the MYB locus and create a 
positive feedback elicited by activation of these enhancers 
by MYB protein, has further enhanced our understanding 
of the biology of tumors that do not harbor chimeric 
MYB transcripts [5]. Finally, the identification of a fusion 
between MYBL1 and NFIB genes in tumors without MYB 
aberration [6, 7], demonstrates that the pathogenesis of 
ACC may be driven by genetic alterations in another 
member of the same transcription factor (TF) gene family. 
Although the MYB and MYBL1 fusion oncoproteins 
emerge as attractive diagnostic markers and therapeutic 
targets to improve clinical management of this lethal 
disease, the manner by which these and other genetic 
alterations initiate and drive ACC progression is not yet 
fully understood, and their impact on clinical outcomes 
remains to be delineated. 
In this review, we summarize the current status of 
the genomic translocations in ACC, discuss challenges 
associated with underpinning their role in ACC 
pathogenesis and focus on possible clinical implications 
stemming from the current research. 
ADENOID CYSTIC CARCINOMA - 
ENIGMATIC AND CHALLENGING 
MALIGNANCY
ACC was first recognized as a distinct head and 
neck neoplasm over 150 years ago by Robin, Lorain and 
Laboulbene, who provided its microscopic description [8]. 
With an incidence of 4.5 cases per million individuals, it 
is the most common malignant tumor of minor salivary 
glands and the second most prevalent cancer of parotid 
and sublingual salivary glands [9, 10]. ACC arises 
sporadically in other exocrine glands located in breast, 
lacrimal glands, nasal passages, tracheobronchial tree, 
prostate, cervix and vulva [9, 11-16]. Interestingly, 
irrespective of the site of origin, these tumors display 
similar histological characteristics and share nonrandom 
cytogenetic anomalies such as copy number alterations 
involving chromosomes 12q, 6q, 8q, 9p, 1p and 22q 
[17-19]. Histologically, these neoplasms are composed 
of two types of cells, inner epithelial/luminal and outer 
myoepithelial cells, recapitulating the structure of 
intercalated ducts of secretory glands from which ACC 
are thought to originate. ACC can be classified into 
three subtypes: tubular and cribiform variants, which 
are characterized by the presence of both epithelial and 
myoepithelial components and display an indolent growth 
pattern, and the solid phenotype, associated with the loss 
of myoepithelial cells and more aggressive biology[20]. 
The clinical behavior of head and neck ACC has 
been described as a “paradox” [8]. While the primary 
tumor often manifests itself as a small and inconspicuous 
nodule with low growth kinetics, the disease displays a 
relentlessly progressive course. Consequently, although 
a patient’s short term prognosis is favorable with 
an expected 5-year survival rate of 77%, rates drop 
significantly after 10 and 15 years with survival estimated 
at 60% and 45% respectively, and most patients dying 
as a result of the disease progression in later decades 
[21]. Additionally, although total resection with a clean 
surgical margin is usually possible, late local relapses 
are likely to occur even after a radical resection and 
adjuvant radiation therapy [11]. The ACC tumors exhibits 
a high tendency for neurotropic invasion leading to deep 
and destructive infiltration of craniofacial region, skull 
base and intracranial cavity [11]. Distant metastases are 
frequently observed in lung, liver and bones as a result of 
hematologic spread, while metastasis to lymph nodes are 
rare. Owing to these highly aggressive characteristics, it 
is not surprising that salivary gland ACC has long been 
recognized as “one of the most biologically destructive 
and unpredictable tumors of the head and neck” [22]. 
Interestingly, ACC localized in the breast exhibits 
favorable clinical characteristics with an excellent 
prognosis, despite a common growth pattern, histology 
and overlapping chromosomal alterations [23].
Until recently, little was known about the molecular 
background of the ACC’s pathogenesis. Non-random 
chromosomal aberrations were observed and reported in 
clinical material since the 1980s, with special attention 
given to the most recurrent t(6;9) rearrangements [24-26]. 
Unfortunately, past efforts to identify the significance of 
this anomaly have been largely hampered by the lack of 
validated ACC cell lines [27]. In 2009, Persson et al. used 
short-lived primary cultures obtained from fresh tumor 
specimens to demonstrate that the t(6;9)(q22-23;p23-24) 
translocation results in a fusion between two TF genes, 
MYB and NFIB [4]. Although this initial study suggested 
that MYB-NFIB fusion might constitute a hallmark of all 
ACC tumors, studies that followed have detected that 
approximately 50% of the ACC patients do not harbor the 
MYB-NFIB translocation [15, 16, 28-31]. These studies, 
however, helped to refine the understanding of MYB-
NFIB fusion oncogene as a specific and common driver 
of ACC pathogenesis in multiple anatomical locations, 
including breast [15, 30], lacrimal glands [16] and skin 
[32, 33]. Furthermore, overexpression of the 5’ fragment 
of MYB was observed in 89-97% [17, 34] of all ACC 
cases, indicating that MYB-NFIB fusion is not the only 
mechanism of MYB overexpression and suggests that 
ACC may also arise from other molecular aberrations 
involving the MYB transcription factor. Indeed, the 
discovery of recurrent alternate rearrangements that 
repose super-enhancers in the NFIB and TGFBR3 loci into 
proximity of MYB gene, uncovers an additional mechanism 
that may drive MYB overexpression in ACC tumors that 
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do not express the fusion transcript [5]. Another subset of 
ACC tumors was found to harbor a novel MYBL1-NFIB 
fusion, an alteration found to be mutually exclusive of the 
“classical” MYB-NFIB rearrangement [6, 7]. The extensive 
homology in the DNA binding domain between MYB and 
MYBL1 and a common change in the gene expression 
signature induced by these fusions strongly suggest that 
pathogenesis of virtually all of ACC tumors is uniquely 
driven by overexpression of members of the MYB TF gene 
family [6].
THE ROLE OF MYB TRANSCRIPTION 
FACTOR FAMILY IN TUMORIGENESIS
MYB, one of the earliest identified proto-oncogenes, 
was discovered almost 30 years ago as a cellular 
homologue of the viral oncogene (v-MYB) carried by 
two different avian leukemia retroviruses, the avian acute 
leukemia virus (AMV) and the E26 virus [35]. MYB is 
a founding member of c-MYB TF family, encompassing 
structurally related MYBL1 (AMYB) and MYBL2 
(BMYB) proteins. It plays a key role in the control of cell 
proliferation, survival, differentiation and angiogenesis 
[35, 36]. Over 80 genes are known as MYB cellular targets, 
including pro-proliferative genes MYC, CCNA1, CCNB1, 
CCNE1, c-KIT, anti-apoptotic BCL-2, HSPA5, HSP70, 
pro-inflammatory COX-2 and differentiation regulator 
genes such as GATA3 [35]. MYB has a vital functional role 
in the establishment of definitive hematopoiesis, inducing 
both expansion and differentiation of progenitor cells of 
erythroid and lymphoid lineages. Additionally, MYB drives 
renewal of colonic epithelium, regulates airway epithelial 
cells differentiation and is a critical player of adult brain 
neurogenesis [35, 37]. 
Ample evidence demonstrates that aberrant MYB 
expression is a potent driver of neoplasia in animal 
and human malignancies. The first evidence of its 
oncogenic potential came from the discovery that viral 
oncogene v-MYB is capable of inducing myeloblastic 
transformation in chickens and quails [35]. v-MYB 
represents a truncated version of the MYB genes and its 
leukemogenic potential has been linked to deletions and 
mutations in its C-terminal regulatory domain [38]. In 
humans, MYB overexpression is detected in most myeloid 
and acute lymphoid leukemia [35]. Its altered activity 
in hematological malignancies is often linked to the 
presence of recurrent chromosomal aberrations, such as 
amplifications, promoter rearrangements or translocations. 
For example, a transforming MYB-GATA1 fusion gene 
has been reported in acute basophilic leukemia [39]. 
Furthermore, high levels of MYB mRNA and protein 
expression were detected in various solid tumors, such as 
colorectal and breast cancers [35]. It has been proposed 
that MYB overexpression commonly seen in these 
malignancies, may partially result from the disruption 
Figure 1: Schematic structure of gene and protein of MYB (A.) and MYBL1 (B). Alternative exons in the genes are shown in a 
lighter color. The 1st intron of MYB contains the attenuation region, whose polyT motifs may induce formation of energetically stable stem 
loop which is predicted to block RNA elongation by RNA Polymerase II stalling. MYB contains miRNA binding sites located in its 3’-UTR 
and involved in repression of its transcriptional activity. MYB and MYBL1 proteins contain evolutionary conserved N-terminal R1, -2, 
-3 repeats forming the DNA binding domain (DBD), and a centrally located transactivation domain (TAD), both essential for the protein 
activity. The negative regulatory domains (NRD) are located in the C-terminal elements of the proteins. Labels indicate conserved domains: 
“FAETL” (which is required for oncogenic activity), “TPTF” motif (conserved in all MYB proteins) and “EVES” domain (involved in the 
negative regulation).
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of the transcriptional elongation blockade imposed 
by the stem-loop poly-T structure formed by genomic 
motifs located in the first intron of MYB transcript. It 
was suggested that this stem-loop structure may lead to 
RNA polymerase II stalling, and subsequently result in 
transcription attenuation [40]. Consistent with this concept, 
it was reported that intronic mutations in the poly-T 
motifs, may reverse the transcriptional arrest and lead to 
increased MYB transcription in colon cancers [41]. In the 
case of breast cancer, relief of the elongation blockade has 
been linked to elevated activity of the estrogen receptor α 
[35]. Moreover, sporadic MYB amplifications, which have 
been reported in BRCA1 positive tumors, may further 
contribute to the overall high levels of MYB expression in 
patients with breast cancer [42]. 
MYB TF consists of three functional domains: 
N-terminal DNA-binding domain (DBD), which 
recognizes a PyAACG/TG consensus sequence, a 
centrally located transcription activation domain (TAD); 
and a negative regulatory domain (NRD), located at 
protein’s C-terminus [40] (Figure 1). Interaction of 
the TAD with several co-repressor and co-activator 
proteins, such as CBP/p300, is essential for induction 
and regulation of MYB transcriptional activity [40, 
43]. The post-translational modifications in NRD, such 
as phosphorylation, acetylation, ubiquitylation and 
sumoylation were shown to affect MYB activity [44-
47]. Studies demonstrate that NRD loss or disruption of 
its leucine zipper-like and EVES-motifs enhances MYB 
activity and subsequently drives neoplastic progression in 
several solid and hematopoietic malignancies [35, 48-50]. 
Involvement of MYB in ACC has been associated 
with a spectrum of complex structural rearrangements, 
of which, the in-frame fusion with the NFIB gene is the 
most prominent (Figure 2). Although multiple breakpoints 
ranging from exon 8 to 3’-UTR of the MYB gene have 
been reported in the fusion positive tumors (Figure 3), the 
minimal common fragment of MYB yet retained within 
the MYB-NFIB chimeric transcripts consists of its first 8 
exons. As a result, critical functional domains of MYB, 
DBD and TAD, are always preserved within the fusion 
oncoprotein and contribute to its transcriptional activity 
[4]. In addition to the fusion of MYB and NFIB, other MYB 
translocations have been incidentally identified in ACC, 
including fusion of MYB exon 14 with intron 3 of the 
PDCD1LG2 gene on chromosome 9p24 or MYB exon 12 
with intron 22 of the EFR3A gene on chromosome 8q24. 
However, the role of these sporadic events has not yet 
been elucidated [29].
MECHANISM OF MYB OVER 
EXPRESSION IN ACC
MYB-NFIB fusion is a dominating mechanism 
of 5’ MYB up-regulation in ACC. Persson et al. have 
postulated that MYB deregulation may be attributed to the 
miRNA target site loss [4]. The 3’ UTR of MYB, which 
is lost as a result of t(6;9)(q22-23;p23-24) translocation, 
contains highly conserved binding sites for certain miRNA 
molecules, including miR-15a, miR-16 and miR-150. It 
was demonstrated that transfection with these miRNAs 
induces a 30% down-regulation of wild-type MYB mRNA 
level in a T-cell acute lymphoblastic leukemia cell line, 
Figure 2: Schematic representation of MYB-NFIB chimeric transcript formation. Translocation between chromosome 6q 
and 9q results in breakpoints in 3’ termini of MYB and NFIB genes, which often take place in the sequences following exon 14 of MYB and 
sequences preceding exon 9 of NFIB. When MYB-NFIB “long fusion” is formed, sequences coding the functional MYB domains (DNA 
binding domain [DBD], Transactivation domain [TAD] and Negative regulatory domain [NRD]) are preserved within the fusion transcript.
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whereas this treatment does not decrease levels of the 
chimeric transcripts in ACC cells [4]. This observation is 
reminiscent of the mechanism observed in lipoma, where 
truncation of another oncogene, HMGA2, and its fusion 
with NFIB results in loss of miRNA target sites, which 
consequently leads to deregulated HMGA2 expression 
[51]. 
Until recently, mechanisms underlying MYB 
overexpression in cases devoid of MYB structural 
aberrations remained largely unclear. It has been shown 
that epigenetic mechanisms such as promoter methylation 
do not play a role in regulation of MYB expression in 
ACC [52]. On the other hand, the role of MYB-targeting 
miRNAs, such as down-regulated in ACC miR-150 [53, 
54], has not yet been fully elucidated. The impact of 
MYB amplification in ACC is probably limited, as copy 
number gains of MYB has been reported only incidentally 
[16, 55] and predominantly in cases already harboring 
“conventional” MYB-NFIB fusion [16]. The most 
attractive mechanism explaining MYB up-regulation 
in tumors without MYB-NFIB fusion are other critical 
translocations bringing regulatory elements into proximity 
of MYB locus. It has been shown that ACCs may harbor 
complex rearrangements, either centromeric or telomeric 
to MYB locus [17]. These structural aberrations may result 
in translocation of segments of chromosome 9, including 
sequences of the NFIB gene, placing them from 0.1 Mb 
to 10 Mb upstream of MYB [6, 17, 29]. This intragenic 
region between MYB and HBS1L contains multiple long-
range enhancer elements, which bring various TFs into the 
proximity of MYB promoter and its negative regulatory 
elements, therefore inducing MYB expression [56, 57]. 
Figure 3: Representation of the breakpoints within the MYB, MYBL1 and NFIB transcripts based on the ‘up-to-date’ 
literature analysis. Black pins represent the breakpoints observed in the MYB-NFIB and MYBL1-NFIB transcripts. Alternative exons 
are shown as boxes below the main transcripts. UTRs are shown in light blue (not to scale). The breakpoint in MYB and MYBL1 have been 
observed in sequences that follow exon 8, thus preserving DBD and TAD within all fusion oncoproteins. The proximal breakpoints (exon 
8, exon 9) lead to formation of a “short fusion”, in which sequences encoding for the NRD are lost, while more distal breakpoints preserve 
the elements of NRD (“long fusion”). In most cases NFIB contributes its terminal exon 9 to the chimeric transcript. In some tumors exons 
8A-8C may also be present in MYB-NFIB mRNA as a result of alternative splicing of NFIB fragment. 3’UTR breakpoints in NFIB have 
also been reported.
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MYB locus is also a common site of retroviral insertion in 
leukemia, with multiple insertion sites localized upstream 
and downstream of the gene [58]. Furthermore, it has 
been observed that translocation of TCRB (T-cell receptor 
beta) gene to region telomeric of MYB, results in MYB 
overexpression in childhood T-cell acute lymphoblastic 
leukemia [58]. The hypothesis suggesting that MYB 
upregulation in ACC is a result of the regulatory element 
translocations, has been confirmed by a recent study. 
It has been reported that rearrangements of enhancers 
located within the NFIB, TGFBR3 or RAD51B loci and 
their relocation upstream or downstream of the MYB 
gene, result in a significant physical interaction of these 
regulatory element with MYB promoter and subsequently 
high level of MYB mRNA expression [5]. Furthermore, 
binding of MYB protein to the translocated enhancers in 
the NFIB and TGFBR3 loci, creates a positive feedback 
loop that fuels further expression of MYB. Interestingly, 
the mechanisms of enhancer-driven overexpression of 
MYB are not limited to ACC, as an analogous event has 
been recently described in angiocentric gliomas, which 
harbor MYB-QKI rearrangements. It has been shown that 
this structural aberration drives tumorigenesis though 
three mechanisms: MYB truncation, fusion oncogene 
overexpression via translocation of enhancer elements 
and hemizygous loss of the QKI tumor suppressor [59]. 
Therefore, it is tempting to speculate that this “single 
event-multiple mechanisms” paradigm may also happen in 
ACC and that the relocation of NFIB regulatory elements 
contributes to high expression of the MYB-NFIB or 
MYBL1-NFIB chimeric transcripts in tumors that harbor 
the in-frame fusions between these genes.
MYBL1 - A PARTNER IN CRIME
MYBL1 (AMYB), a gene located at chromosome 
8q, is another member of the MYB gene family. Although 
MYBL1 protein and MYB share extensive structural 
homology in the DNA binding domain (Figure 1), and 
activate the same reporter genes in vitro, they exhibit 
distinct biological functions [60, 61]. In a series of 
deletion and domain swap experiments, Lei et al. have 
demonstrated that individual functional elements within 
the TAD, NRD and the C-terminus domains may play 
a crucial role in the target specificity of different MYB 
family members, providing a possible explanation 
for their diverse functionality [62]. MYBL1 has been 
recently shown to be implicated in the oncogenesis of 
diffuse astrocytoma, which were discovered to harbor 
recurrent rearrangements in chromosome 8q, resulting 
in tandem duplication/truncation of the MYBL1 gene. 
Consequently, the MYBL1 transcript truncated at exon 9 
was shown to have oncogenic properties [63, 64]. The 
recently discovered MYBL1-NFIB fusion gene, a result 
of t(8q;9p) translocation, provides another example of 
MYBL1 neoplastic potential. The structure of the MYBL1-
NFIB fusion gene exhibits a striking similarity to the 
MYB-NFIB fusion, with MYBL1 breakpoints identified in 
exons 8, 9, 14 and 15, preserving the DNA binding and 
transactivation domains in all fusion proteins [6] (Figure 
3). This fusion is mutually exclusive to the “classical” 
MYB-NFIB translocation and induces the overexpression 
of transcriptionally active 5’- MYBL1 fragment [6, 7]. 
In a subset of ACCs, other MYBL1 rearrangements were 
also observed, such as fusion with YTHDF3 or MYBL1 
3’- truncation, resulting in a similarly abnormal expression 
profile [6, 7]. Since, in the context of the fusion, both 
MYB and MYBL1 lose elements responsible for their 
target specificity, the resulting oncoproteins may induce 
common expression signatures. Indeed, it was previously 
demonstrated that all ACC share similar expression 
profile, regardless of MYB-NFIB fusion status or level of 
MYB expression [53]. Common transcriptome signatures 
found in tumors harboring MYB-NFIB and MYBL1-NFIB 
fusions, further corroborate these findings [6, 7].
IMPLICATIONS OF VARIABLE 
STRUCTURE OF MYB AND MYBL1 IN 
THE FUSION TRANSCRIPTS
Past studies of the transcriptional activity of MYB 
suggest that alternately spliced RNA forms of MYB may 
produce proteins with different quantitative and qualitative 
activities [50]. Indeed, recent observations demonstrate 
that the structure of MYB fusion transcripts may also 
implicate varying level of oncogenic potential. Certain 
MYB-NFIB and MYBL1-NFIB transcripts preserve their 
respective NRD as a result of distal breakpoint (“long 
fusion”), whereas other fusion products lose it as a results 
of a breakpoint located in proximity of exon 8 (“short 
fusion”). It has been previously reported that the highest 
expression levels of the fusion mRNA transcripts are 
commonly observed in cases harboring a breakpoint in 
exon 8 of MYB [28, 29]. Recent studies suggest that “long” 
and “short” fusion genes may actually differ in regards to 
their target specificity and transcriptional activity. Mitani 
et al. [6] identified that a cohort of ACC harboring MYB 
or MYBL1 breakpoint after exon 11 exhibits a distinct 
expression profile, which differs from tumors with fusions 
at exon 8 or 9. The first group was enriched for expression 
of 19 gene sets predominantly involved in RNA processing 
and regulation of translation, while the latter group was 
enriched for 5 gene sets related to tissue development [6]. 
Another study demonstrated that transfection with different 
MYB-NFIB and MYBL1-NFIB fusion genes activates the 
same synthetic promoters containing MYB binding sites, 
although the magnitude of activation differs significantly 
between fusion constructs. The transfection with the wild-
type MYB gene or “long fusion” MYB-NFIB constructs 
containing transformation and negative regulation motifs 
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resulted in 100-fold activation of the 5xMRE-Luc reporter, 
while overexpression of the “short fusion” MYB-NFIB 
or 3’-truncated MYB resulted in approximately 200 to 
600 fold activation [7]. Although analogous findings 
were observed in regards to MYBL1 and MYBL1 fusion 
constructs [7], the clinical implications of these findings 
are unclear and warrant further investigation. 
ROLE OF NFIB GENE IN ACC 
PATHOGENESIS
Contrary to MYB, the role of NFIB (Nuclear Factor 
I B) in normal and cancer cell biology remains obscure. 
NFIB is a member of the Nuclear Factor I gene family, 
also known as ‘CAAT box TFs’ (CTF). NFIB binding 
sites have been identified in the promoter, enhancer and 
silencer elements of over 100 cellular and viral genes, 
although the exact function of most of them is poorly 
understood [65]. Studies suggest that upon dimerization 
and association with its target, NFIB may modulate 
transcriptional activation or repression of specific gene 
promoters in a tissue-specific manner [65]. The diverse 
cellular functions of NFIB are further corroborated by 
studies reporting its oncogenic or tumor suppressor roles 
in different tumor types. For example, NFIB inactivation 
was shown to contribute to osteosarcoma progression [66] 
and cutaneous carcinogenesis [67], while other studies 
demonstrates that NFIB may acts as an oncogene in 
small cell lung cancer [68]. A study conducted in NFIB-
deficient mice model demonstrated that this TF plays a 
key role in tubule cell differentiation during embryonic 
development of submandibular glands [69]. Additionally, 
the loss of NFIB gene leads to fetal lung maturation 
defects in heterozygous NFIB-deficient mice, indicating 
possible NFIB haploinsufficiency [70]. Recently, it has 
been shown that ACC tumors, regardless of the fusion 
status, overexpress NFIB as compared to normal salivary 
gland tissue [71]. Although the functional significance 
of this upregulation is not yet clear, it may be speculated 
that the elevated NFIB expression is a result of MYB TF 
interaction with NFIB gene enhancers [5].
Although the NFIB fragment present within the 
MYB-NFIB fusion content may differ as a result of 
alternative splicing, the exon 9 (encoding the last 5 amino 
acids) is present in virtually all chimeric mRNA transcripts 
(Figure 3) [4]. It has been suggested that due to its small 
size, the contribution of this coding fragment to the 
properties of the fusion oncoprotein is likely very limited 
[4]. However, it is important to note that exactly the same 
fragment of NFIB is fused with HMGA2 and HMGIC 
genes in lipoma [72] and pleomorphic adenoma [73], 
respectively. HMGA2-NFIB fusion strongly resembles 
the rearrangement between MYB and NFIB, as in both 
instances the aberration results in highly deregulated 
expression of DNA-binding domains of the TF linked to 
the small C-terminal fragment of NFIB. Hence, although 
the exact role of NFIB as a fusion partner remains to be 
discovered, it is possible that NFIB contributes stabilizing 
or regulatory elements to the fusion protein [34]. On the 
other hand, it has been reported that in some cases, NFIB 
fragment within the MYB-NFIB mRNA may be limited 
to its 3’ UTR only (our unpublished observations in ACC 
samples further support these findings) [29]. Furthermore, 
NFIB translocations have been reported in FISH t(6;9)-
positive/MYB-NFIB-transcript negative ACCs, resulting 
in fusions between the 5’-part of NFIB and miscellaneous 
partner genes, such as XRCC4, PTPRD, NKAIN2 or 
AIG1 [6, 29]. Additionally, our lab has recently reported 
presence of NFIB fusions with the RIMS1, MAP3K5, 
RPS6KA2, MYO6 genes, all of which are located on 
chromosome 6q [71]. It is uncertain whether these 
fusions produce functional proteins contributing to 
oncogenesis per se. However, it was noted that cases 
harboring these alternative NFIB gene rearrangements, 
have NFIB segments relocated into the proximity of the 
MYB locus and concurrently overexpressed the intact MYB 
transcript [6]. As discussed above, it is possible that these 
rearrangements relocate NFIB-associated super-enhancers, 
resulting in their physical interaction with MYB promoter 
and augmented expression of MYB mRNA [5]. 
INCIDENCE OF THE STRUCTURAL 
ABERRATIONS IN ACC
The incidence of MYB-NFIB fusion varies across 
studies with reported rates ranging from 23% to 86% 
(Table 1). Several possible explanations for the disparities 
across studies may be suggested, e.g. different anatomical 
location of tumors tested, variable quality/origin of 
material studied (archival FFPE vs. frozen tumors), or 
different analytical methods used (RT-PCR, FISH, RNA-
sequencing, WGS). For example, when assessed with 
RT-PCR, a higher incidence of MYB-NFIB fusions was 
reported in fresh-frozen material than in FFPE samples 
(86% vs. 44% respectively) [34]. Furthermore, it has 
been reported that positive FISH status may not always 
be associated with the chimeric MYB-NFIB transcript 
formation. In a subset of these ‘nontranscript forming’ 
tumors, breakpoints at the flanking sites of MYB have 
been identified (in many instances involving the NFIB 
segments) [5, 29]. Similarly, NFIB fusions with genes 
other than MYB that are located on chromosome 6q can 
also account for this discrepancy [71]. Consequently, 
our summary, which includes all up-to-date studies 
investigating the incidence of the MYB-NFIB fusion in 
ACC, indicates that t(6;9) rearrangement was observed 
in 57% (127/223) of all ACC tumors analyzed using in 
situ hybridization techniques, and the chimeric mRNA 
transcript was detectable in 51.1% (162/317) of the tumors 
(Table 1).
The second known fusion, MYBL1-NFIB, has been 
reported independently by three studies to be present in 
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Table 1: Reported incidence of MYB and MYBL1 rearrangements in ACC categorized by the detection methodology 
used.
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11% of the ACC cases [6, 7, 71]. Our team has detected a 
similar incidence of this novel fusion, with 7/56 (12.5%) 
of ACCs identified as MYBL1-NFIB positive (unpublished 
data; manuscript in preparation). MYBL1-NFIB fusion 
was found to characterize 19% of all cases that do not 
harbor any MYB fusions. Additional structural aberrations 
involving MYBL1, such as fusion with YTHDF3, or 
MYBL1 transcript truncations, have been identified in 6% 
of ACC tumors [6]. Taken together, the MYB and MYBL1 
gene rearrangements are observed in approximately two-
thirds of all ACC cases.
Another subset of ACCs with no structural 
aberrations involving MYB or MYBL1 genes, commonly 
overexpresses the intact MYB mRNA transcript. 
Collectively, this group contains tumors which harbor 
t(6;9) that do not result in formation of the MYB-NFIB 
transcript, and ACCs with no known t(6;9) translocations 
[6]. In the light of the recent discoveries, it appears that 
enhancer rearrangements in the vicinity of the MYB locus 
may account for MYB upregulation in the majority of 
these cases, however further studies are warranted to 
unravel alternative events that may also lead to MYB 
overexpression. 
Comprehensive genetic studies identified low 
rates of somatic mutations in ACC tumors (0.3 somatic 
mutations per 1 Mb) with wide mutational diversity 
scattered among genes involved in chromatin remodeling, 
DNA damage/checkpoint, FGF-IGF-PI3K, Rho family, 
axonal guidance, Notch and MYB-MYC signaling 
pathways [15, 71, 74, 75]. Mutations in NOTCH1 and 
SPEN, a negative NOTCH signaling regulator, were 
reported to be preferentially found in tumors with no 
MYB or MYBL1 fusions [6]. Interestingly, another study 
has shown that MYB signaling cooperates with distinct 
pathways in eliciting biphenotypical differentiation of 
ACC cells, with myoepithelial cells enriched for TP63 
signaling, abd Notch signal orchestrating expression 
program in luminal cells [5]. Absence of myopithelial 
component in solid histology high grade tumors has 
been found to be associated with activation of Notch 
signaling by gain-of-function mutation in NOTCH1 or 
loss-of-function aberrations in SPEN [5]. Therefore, while 
dependency on Notch signaling has been associated with 
more aggressive phenotype, it implies that this group of 
ACC patients may respond to the targeted therapy with 
NOTCH1 inhibitors, as confirmed by a recent tumor 
xenograft study [76]. 
It is also possible that a number of cases which do 
not demonstrate aberrant expression of MYB or MYBL1 
may represent other types of salivary gland tumors with an 
ACC-like morphology, such as  polymorphous low-grade 
adenocarcinoma (PLGA) or basal cell adenocarcinoma 
[77]. The problem of histological overlap between 
different salivary gland tumors may be exemplified by a 
report which identified an instance of MYB-NFIB fusion 
in a tumor diagnosed as PLGA [78]. However, it was 
recently discovered that PLGAs are characterized by a 
highly recurrent and pathognomonic hotspot mutation in 
the PRKD1 gene [79], demonstrating that PGLA and ACC 
are genetically distinct entities. Future comprehensive 
studies may shed light on whether precise diagnosis and 
classification of salivary gland tumors based solely on 
molecular characteristics will be possible. 
IMPACT OF MYB AND MYBL1 
ABERRATIONS ON CLINICAL 
OUTCOMES
High recurrence of MYB-NFIB fusions and their 
ACC-specificity in the context of other types of head 
and neck neoplasms [4, 28] have encouraged various 
attempts to assess the diagnostic relevance of these genetic 
aberrations. Hudson et al. utilized FISH to detect MYB 
structural aberrations in cytological material obtained via 
fine-needle aspiration biopsy of primary and metastatic 
ACC tumors. Using this approach, they were able to 
successfully identify 5 out of 10 ACCs and distinguish 
them from pleomorphic adenomas (PA), which did not 
demonstrate MYB abnormalities in any of the studied cases 
[55]. The clinical utility for the detection of MYB protein 
overexpression in ACCs has also been evaluated in similar 
cytological material, with fine-needle aspiration biopsy 
specimens from ACCs found positive for MYB in most of 
the studied cases, successfully discriminating them from 
pleomorphic adenomas [80, 81]. 
Despite its potential diagnostic value, there is no 
consensus on the utility of MYB and MYBL1 fusions as 
prognostic markers. It has been reported that MYB-NFIB 
fusion status is not significantly associated with overall 
survival [28, 82], although a trend toward higher likelihood 
of local recurrence, perineural invasion and decrease in 
disease-free survival (DFS) has been observed [6, 31, 
82]. On the other hand, MYB overexpression regardless 
of the fusion status has been significantly associated with 
a poor patient survival [29]. Furthermore, combined MYB 
and MYBL1 expression was shown to be associated with 
a higher disease stage and poor clinical outcome [7]. 
Intriguingly, a difference in the outcomes of patients with 
MYB and MYBL1 alterations has been recently revealed, 
with the former group showing a significantly shorter 
survival [6], although studies conducted in larger cohorts 
of ACC patients are essential to delineate clinical impact 
of this finding. 
MYB TRANSCRIPTION FACTOR AS A 
THERAPEUTIC TARGET
Treatment options available to ACC patients remain 
limited to surgery and/or radiation and efficiency of 
currently available chemotherapeutic agents is extremely 
low [83]. Recurrent MYB alterations observed in ACC 
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may therefore present an attractive target for potential 
therapeutic interventions. Unfortunately, inhibition 
of TF activity has been historically proven to be 
challenging. With no kinase activity, ligand binding sites 
or hydrophobic pockets that may be targeted by small 
molecule inhibitors (with exception of nuclear hormone 
receptors), inhibition of TF activity requires disruption 
of complex protein-DNA or protein-protein interactions 
[84]. Nonetheless, success in blocking protein-protein 
interactions, illustrated by the development of a direct 
NOTCH1 inhibitor [85], are encouraging and suggest that 
this strategy might be viable. Furthermore, it was shown 
that direct inhibition of other aberrant transcription factors, 
such as CBFβ-SMMHC fusion protein in AML, appears to 
be feasible [86].
The possibility of targeting MYB protein has 
predominantly been explored in leukemia studies, and 
several molecular approaches have been proposed 
(reviewed by Pattabiraman et al. [40]). One of these 
approaches suggests the use of antisense nucleotides or 
RNA interference to suppress MYB expression. Although 
this method proved to be successful in a mouse model of 
AML [87], use of RNA inference in clinical trials has been 
associated with substantial toxicity and problems with 
delivery [40]. Another approach aiming at suppression 
of the MYB protein expression proposes to target protein 
complexes that relieve the elongation blockade imposed 
by the poly-T motifs located in the first intron of MYB 
(see above). Deregulation of the interaction between these 
complexes (involving NF-kB and c-Jun) [88, 89] and 
the intronic region of MYB might constitute an attractive 
therapeutic strategy [40]. As MYB activity is regulated by 
an interplay with various partner proteins such as CBP/
p300 co-activator, disruption of their physical associations 
might pose as another promising approach to reduce 
MYB activity in cancer. Interaction between the MYB 
transactivating domain and the KIX domain of CPB/p300 
has been evaluated in depth by nuclear magnetic resonance 
studies [90], providing important information which may 
guide the development of inhibitors that could specifically 
bind to the protein surfaces. This strategy has been 
recently successfully utilized for establishment of two 
small molecule inhibitors of the MYB/p300 interaction, 
Naphthol AS-E phosphate and triterpenoid Celastrol, 
which were shown to impose the inhibitory effect on MYB 
[91, 92]. Another study was utilizing screens of small-
molecule libraries and identified a promising specific 
inhibitor of MYB activity, natural sesquiterpene lactone 
mexicanin-I [93]. Although subsequent studies revealed 
even more potent inhibitors of MYB in the sesquiterpene 
lactone group, the exact mechanism of their action and 
their clinical utility remain to be delineated [94]. Finally, 
dependence of MYB expression on the activity of super-
enhancers with strong bromodomain protein occupancy, 
suggests that use of BET bromodomain inhibitors may 
render potential anti-tumorigenic response in ACC [5]. 
BET inhibitors were shown to have oncostatic effect 
on ACC xenografts by disrupting MYB circuitry, as 
suggested by a modest decrease in MYB level and MYB 
target gene expression. This effect was however restricted 
to grade 2 tumors, as solid phenotype tumors (grade 3) 
exhibited resistance to BET inhibition, possibly reflecting 
their stronger dependency on NOTCH signaling, which in 
turn may be potentially circumvented by Notch inhibitors 
[5].
Targeting the downstream effectors of MYB, such as 
c-KIT, could pose an alternative approach to reduce MYB 
activity. c-KIT is a strong oncogene involved in leukemia, 
gastrointestinal stromal tumors (GIST) and melanoma 
[95-97], and its inhibition with imatinib has proven to 
be a highly successful strategy for management of these 
diseases. Unfortunately, although c-KIT overexpression 
is observed in 95% of ACCs [98], clinical trials with 
imatinib or second generation c-KIT inhibitors, such 
as dasatinib, produced no objective responses in ACC 
patients [83]. This has been attributed to the lack of c-KIT 
gain-of-functions mutations (which are vital for c-KIT 
overexpression in GIST) among the ACC tumors [20, 99]. 
BCL-2, a key pro-survival molecule and a MYB target, 
is also overexpressed in a vast majority of ACCs [98]. 
The development of selective BCL-2 inhibitors [100, 
101] may open up a fertile avenue for novel therapeutic 
opportunities, but their utility in ACC has not yet been 
evaluated. Although inhibitors of other MYB downstream 
targets, such as COX-2, are currently available [98], given 
the broad and complex transcriptional activity of MYB, 
it is unlikely that targeting a single effector molecule will 
emerge as a successful strategy. 
CONCLUSIONS
The identification of recurring t(6;9) and t(8;9) 
chromosomal translocations resulting in MYB-NFIB and 
MYBL1-NFIB fusion oncogenes and the unravel of the 
role of super-enhancer translocations in the oncogene 
activation, dramatically extend our understanding of the 
role of the MYB transcription factors in the pathogenesis 
of ACC. New findings solidify our knowledge on the 
involvement of the complex structural alterations in 
head and neck neoplasias and indicate that disruption 
of regulatory mechanisms may play vital roles in 
overexpression of these potent oncogenes. Although the 
exact biological consequences of these events are not yet 
entirely clear, the technical progress in genomic profiling 
and new experiment models of ACC, such as a recently 
developed cell line [102] and patient-derived xenografts 
[103], may significantly aid in uncovering the impact of 
these genetic events on ACC pathogenesis. Furthermore, 
advancements in pharmacogenetics indicate that the MYB 
protein, previously regarded as an “undruggable” target, 
may be potently inhibited with novel promising agents. 
In this context, there is growing hope that intensified 
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efforts will become fruitful with the emergence of new 
diagnostic and therapeutic avenues that will improve 
clinical outcomes for ACC patients.
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